U.S. Food and Drug Administration
Watson's Generic Lybrel(R) Receives FDA Approval
Published in Women's Health Weekly, June 23rd, 2011
2011 JUN 23 -- Watson Pharmaceuticals, Inc. (NYSE: WPI) announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for Levonorgestrel and Ethinyl Estradiol Tablets, USP, 0.09 mg/0.02 mg, the generic equivalent to Pfizer's Lybrel® tablets. Watson expects to launch the product shortly.
Lybrel® had total U.S. sales of just under $12 million for the twelve months ending April 30, 2011, according to IMS Health. Lybrel® tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
More Articles from Women's Health Weekly
- Breast Cancer
A decade dedicated to breast cancer care advocacy garners ASCO Award for researcher - Bone Research
Data on Bone Research Detailed by Researchers at National Institutes of Health - Breast Cancer
Data on Breast Cancer Described by R.R. Paulinelli et al - Cervical Cancer
Data on Cervical Cancer Published by Researchers at University of Arizona - Menopause
Data on Menopause Detailed by Researchers at Fred Hutchinson Cancer Research Center - Breast Cancer
Einstein scientists find crucial molecule involved in spread of breast cancer - More from this issue of Women's Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
